Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Bladder Cancer Treatment Market Outlook

The bladder cancer treatment market size was close to USD 4.03 billion in 2023, driven by the rising number of bladder cancer cases. The bladder cancer treatment market is likely to grow at a CAGR of 9.31% during the forecast period of 2024-2032 to reach a value of USD 8.98 billion by 2032, driven by the rise in unhealthy lifestyles.

bladder cancer treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Bladder Cancer Insights

Bladder cancer develops in the tissues of the urinary tract and is known as urological cancer. Cell division occurs uncontrollably in the epithelium and can spread into the bladder's muscular wall.

There is still no clear understanding of what causes bladder cancer. Depending on the type of cancerous cells, bladder cancer can be divided into three categories. The following types are: 

Transitional Cell Carcinoma: This type of cancer is also called urothelial carcinoma. The disease occurs in bladder lining cells called urothelial cells. Among all bladder cancer types, this is the most common one.

Squamous Cell Carcinoma: A prolonged infection or stimulation leads to the development of this type of cancer in the bladder.

Adenocarcinoma: Bladder cancer occurs in glands located in the bladder lining. There are only a few cases of this type of bladder cancer.

There are several ways in which non-muscle invasive bladder cancer can be detected, including blood tests, urine cytology, cystoscopy, and computerised tomography. 

Chemotherapy, immunotherapy, or surgery are the preferred treatment methods for bladder cancer. 

On the other hand, prolonged exposure to radiation, tobacco consumption, chronic bladder infections, and smoking are among the risk factors. Any age group is susceptible to this condition. The condition is more common in older adults. Additionally, smoking is the leading cause of bladder cancer in the world.

According to the market research report, the bladder cancer treatment market can be categorised into the following segments: 

bladder cancer treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Type

  • Invasive Bladder Cancer
    • Non-Muscle-Invasive Bladder Cancer
    • Muscle-Invasive Bladder Cancer
  • Transitional Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Others

Market Breakup by Diagnosis Method

  • Cystoscopy
  • Biopsy
  • Urine Cytology
  • Imaging Tests

Market Breakup by Treatment Method

  • Surgery
  • Intravesical Chemotherapy
  • Systemic Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

bladder cancer treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The bladder cancer treatment market growth is expected to be influenced by unhealthy lifestyles, such as bladder infections, genetic abnormalities, smoking, and chemical exposure. The bladder cancer treatment market is further expected to grow due to improvements in cancer treatment methods.

The market growth is predicted to be driven by an aging population as well. Increased treatment costs will further limit the growth of the market over the long term. Moreover, emerging markets offer opportunities for market growth. The bladder cancer therapy market, however, may be further hampered by post-treatment side effects.

North America Dominates the Global Bladder Cancer Treatment Market

The market in North America is largely driven by technological advances in medicine, especially cancer treatment. Moreover, bladder cancer treatment will benefit from increased healthcare spending in this region. 

Research and development are expected to drive the bladder cancer treatment market growth in Asia-Pacific. 

The availability of generic drugs and government awareness programs are also expected to generate significant growth in this region over the next few years.

Therapeutic Landscape

Currently, researchers are testing immune checkpoint inhibitors for bladder cancer in the early stages and in combination with other treatments. The research includes: 

  • A drug called nivolumab (Opdivo) has been approved by the United States Food and Drug Administration in 2021, as an additional (adjuvant) treatment for patients with urothelial cancer who are at high risk of recurrence after surgery. It was the first FDA approval for this type of adjuvant treatment.
  • Avelumab (Bavencio), an immune checkpoint inhibitor, was approved by the FDA in 2020 for patients with advanced bladder cancer which has shrunk or stopped growing after receiving platinum-based chemotherapy. 

Avelumab has been approved for the adjuvant treatment of bladder cancer that has not metastasized (locally advanced) or that has spread beyond the bladder (metastatic carcinoma).

Clinical Trial

Bladder cancer treatment depends on the type and stage of the disease. Research on new treatments and drugs is ongoing in addition to new combinations of existing treatments. 

Drugs used in targeted therapy target specific cancer cells while causing little damage to normal cells. FDA approved erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial cancer in 2019. 

A patient with an altered FGFR2 or FGFR3 gene may benefit from this medicine. It is estimated that FGFR gene mutations are responsible for 20% of bladder cancer cases. 

Patients with advanced bladder cancer and mutations in the FGFR gene are undergoing a phase 3 trial that compares erdafitinib with standard chemotherapy and pembrolizumab. 

The purpose of this study is to determine whether erdafitinib or an immune checkpoint inhibitor may be more beneficial in treating FGFR-mutant bladder cancer patients than chemotherapy.

In phase 3 trials, patients with muscle-invasive bladder cancer are receiving chemotherapy and radiation therapy with and without immune checkpoint inhibitor atezolizumab. Radiation therapy and chemotherapy combine to kill more cancer cells than chemotherapy alone. Patients with muscle-invasive bladder cancer may achieve better outcomes when atezolizumab (Tecentriq) is combined with radiation therapy and chemotherapy. 

The monoclonal antibodies are proteins made in the laboratory and can bind to specific targets in the body, such as cancer cells. Monoclonal antibodies are chemically linked to drugs to form antibody-drug conjugates. It can kill cancer cells without harming normal cells. 

Enfortumab vedotin-ejfv (Padcev) is also approved for treating advanced or metastatic bladder cancer. Positive results have been observed in patients who have previously been treated with chemotherapy and immune checkpoint inhibitors. A study is ongoing to determine whether this drug can be used together with immunotherapy and/or chemotherapy to treat bladder cancer early.

Competitive Landscape

The report gives an in-depth analysis of the top players involved in the global bladder cancer treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Celgene Corporation
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Sanofi S.A.
  • Merck & Co. Inc.
  • Genetech Inc.
  • Johnson & Johnson Services, Inc
  • Viventia Bio Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Herantis Pharma Plc.
  • Taris Biomedical LLC
  • Prometic Life Sciences Inc.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Diagnosis Method
  • Treatment Method
  • Treatment Channel
  • Region
Breakup by Type
  • Invasive Bladder Cancer
  • Transitional Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Others
Breakup by Diagnosis Method
  • Cystoscopy
  • Biopsy
  • Urine Cytology
  • Imaging Tests
Breakup by Treatment Method
  • Surgery
  • Intravesical Chemotherapy
  • Systemic Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Celgene Corporation
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Sanofi S.A.
  • Merck & Co. Inc.
  • Genetech Inc.
  • Johnson & Johnson Services, Inc
  • Viventia Bio Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Herantis Pharma Plc.
  • Taris Biomedical LLC
  • Prometic Life Sciences Inc.

Bladder Cancer Treatment Market Report Snapshots

Bladder Cancer Treatment Market Size

Bladder Cancer Treatment Market Growth

Bladder Cancer Treatment Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market is likely to grow at a CAGR of 9.31% during the forecast period of 2024-2032.

The market attained a value of USD 4.03 billion in 2023.

The market is expected to reach a value of USD 8.98 billion by 2032.

The factors stimulating the development of the market are bladder infections, genetic alteration, smoking, and chemical exposure, and a rise in R&D expenditure in biopharmaceutical companies.

Lack of awareness and rising treatment cost are the suspected reasons for hindering the growth of this market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.

The top companies involved are AstraZeneca Plc., Bristol-Myers Squibb Co., Celgene Corporation, Pfizer Inc., GlaxoSmithKline Plc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., Merck & Co. Inc., Genetech Inc., Johnson & Johnson Services, Inc, Viventia Bio Inc., Spectrum Pharmaceuticals, Inc., Herantis Pharma Plc., Prometic Life Sciences Inc., and Taris Biomedical LLC.

The detection of non-muscle invasive bladder cancer can be done through blood tests, urine cytology, cystoscopy, or computerised tomography.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124